NeuroMab™ Anti-PSK9 Antibody(NRP-0422-P1534)

Product Overview

Description

The anti-PCSK9 antibody shows binding specificity for PCSK9 and blocks the interaction of PCSK9 with LDLR. The anti-PCSK9 antibody can be used for the diagnosis, assessment and treatment of diseases and disorders associated with PCSK9.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Rabbit; Humanized

Applications

ELISA; Block; Inhib; In Vitro; In Vivo

Relevant Diseases

Alzheimer's Disease; Stroke; Neuroinflammation

Product Properties

Formulation

PBS only

Preservatives

BSA Free

Concentration

1mg/mL

Purification

Purified recombinant IgG prepared by affinity chromatography on Protein A from a mammalian cell line

Purity

> 95% (SDS-PAGE)

Endotoxin Level

Regular Endotoxin < 5 EU/mg
Low Endotoxin < 1 EU/mg

Shipping

Gel Packs

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Research Use Only

For research use only

Target

PSK9

Official Name

PCSK9

Full Name

Proprotein Convertase Subtilisin/Kexin Type 9

Alternative Names

Proprotein Convertase Subtilisin/Kexin Type 9; Subtilisin/Kexin-Like Protease PC9; NARC-1; NARC1; PC9; Convertase Subtilisin/Kexin Type 9 Preproprotein; Hypercholesterolemia; Autosomal Dominant 3; Neural Apoptosis Regulated Convertase 1; Neural Apoptosis-Regulated Convertase 1;

Gene ID

100102(Human)

Uniprot ID

Q80W65(Human)

Product Pictures

ELISA

Figure 1 provides binding data of anti-PCSK9 antibodies to human PCSK9 of antibodies Ab11, Ab12.

Inhib

Figure 2 Inhibition of LDL uptake using antibodies Ab10, Ab11 and Ab12.

Inhib

Figure 3 Inhibition data of anti-PCSK9 antibody Ab11 blocking the interaction between PCSK9 and LDLR.

Inhib

Figure 4 presents data showing the percent change in serum LDL-C cholesterol levels in Abl 1 -injected cynomolgus monkeys relative to pre-dose levels.

Publications